EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights

Shivani Handa iD, Kyle A Farina, Michelle Becker iD, Brianna Kelly, Ashley Yu iD, Jonathan Feld, Douglas Tremblay, Bridget K Marcellino, Christian Salib iD, John Mascarenhas iD, Alan H Shih iD

JCO Precision Oncology · 2024-02 · (8)

DOI: 10.1200/po.23.00234 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCO Precision Oncology, 2024-02. Verfasst von Shivani Handa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report the first case of pacritinib-withdrawal syndrome with in vitro elucidation of underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHumansBridged-Ring CompoundsPyrimidinesJanus Kinase 2

Substanzen

Bridged-Ring CompoundsPyrimidinesJAK2 protein, humanJanus Kinase 2

Autor:innen und Institutionen

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Pharmacy Practice, The Mount Sinai Hospital, New York, NY.
  • Department of Pathology, Molecular & Cell-Based Medicine, Icahn School of Medicine, The Mount Sinai Hospital, New York, NY.

ORCID-Profile: Shivani Handa, Michelle Becker, Ashley Yu, Christian Salib, John Mascarenhas, Alan H Shih

Zitieren

APA

Handa, S., Farina, K. A., Becker, M., Kelly, B., Yu, A., Feld, J., Tremblay, D., Marcellino, B. K., Salib, C., Mascarenhas, J., & Shih, A. H. (2024). Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO Precision Oncology. https://doi.org/10.1200/po.23.00234

Vancouver

Handa S, Farina KA, Becker M, Kelly B, Yu A, Feld J, et al. Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights. JCO Precision Oncology. 2024. doi:10.1200/po.23.00234

BibTeX
@article{Handa2024,
  author = {Handa, Shivani and Farina, Kyle A and Becker, Michelle and Kelly, Brianna and Yu, Ashley and Feld, Jonathan and Tremblay, Douglas and Marcellino, Bridget K and Salib, Christian and Mascarenhas, John and Shih, Alan H},
  title = {Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights},
  journal = {JCO Precision Oncology},
  year = {2024},
  number = {8},
  doi = {10.1200/po.23.00234}
}
Kostenlos starten →